Bladder Cancer | Tumor

CURE’s bladder cancer page is a go-to resource for oncology news and updates in the world of bladder cancer. Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in bladder cancer.

FDA Approves First Targeted Therapy to Treat Metastatic Bladder Cancer

April 12th 2019

The Food and Drug Administration granted accelerated approval to Balversa to treat locally advanced or metastatic bladder cancer with a type of susceptible genetic alterations known as FGFR3 or FGFR2, in patients who have progressed during or following prior platinum-containing chemotherapy.

Investigational Therapy Shows Promise in Advanced Bladder Cancer

April 11th 2019

A percentage of patients with urothelial carcinoma saw their disease shrink or disappear after treatment with enfortumab vedotin in a phase 2 clinical trial.

The Future of Immunotherapy for Bladder Cancer

March 14th 2019

An expert discusses the future of immunotherapy in light of new frontline treatments like Keytruda that have been demonstrating positive results for patients with non–muscle invasive bladder cancer.

Frequent Infections May Lead to Delayed Cancer Diagnoses in Women

March 13th 2019

Women with frequent urinary tract infections (UTIs) were more likely to experience lower quality diagnostic processes when it comes to screening for bladder and kidney cancer.

Radical Cystectomy: Risk Versus Reward for Patients With Bladder Cancer

March 13th 2019

Although muscle-invasive disease is often treated by removal of the bladder, experts reveal potential high risk of death.

Past, Present and Future: 'Immunotherapy is Here to Stay'

March 12th 2019

At the 2019 Genitourinary Cancers Symposium, Arjun V. Balar discussed the past, present and future of immunotherapy for the treatment of bladder cancer.

Mediterranean Diet Associated With Lower Risk of Bladder Cancer

March 11th 2019

After a review of more than 600,000 people, researchers discovered an association between foods consumed and bladder cancer risk.

Highly Sensitive Urine Test Could Be a Better, Less Invasive Tool for Bladder Cancer

February 22nd 2019

Using tumor DNA found in urine, researchers believe they have found a method to diagnose and monitor bladder cancer that outperforms standard tests.

Keytruda May Play a Role in Treatment of Patients with Non-Muscle Invasive Bladder Cancer

February 21st 2019

After patients with non–muscle invasive bladder cancer fail to respond to treatment with BCG immunotherapy, Keytruda (pembrolizumab) may induce responses in these high-risk patients.

FGFR3 Inhibitor Shows Promise in Advanced Bladder Cancer

February 20th 2019

Vofatamab (B-701) may be safe and effective for patients with locally advanced or metastatic bladder cancer with an FGFR3 mutation who have relapsed after, or are refractory to, at least one prior line of chemotherapy, according to preliminary findings.

Computer Model May 'Offer Better Picture' of Who Benefits from Bladder Cancer Therapy

February 13th 2019

An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.

Bladder Cancer Treatment Without Removing the Organ is Effective

January 18th 2019

Although chemotherapy and radical cystectomy are traditionally used to treat muscle-invasive disease, a recent analysis shows similar overall survival outcomes in patients treated with chemoradiotherapy.

Risk for Heart Attack, Stroke Five-Fold in Older Patients One Month Before Cancer Diagnosis

January 18th 2019

Older adults may be at an increased risk for a heart attack or stroke five months before they are even diagnosed with cancer – a risk that peaked in the month prior to diagnosis, according to a report published in Blood.

Contrary to Previous Studies, Sex May Not Impact Efficacy of Immunotherapy

January 10th 2019

A recent meta-analysis has found no noticeable difference in immunotherapy’s efficacy based on patient sex.

Clinical Trials Play Key Role in Future of Bladder Cancer

November 29th 2018

While the treatment landscape continues to grow in bladder cancer, researchers should continue to follow the evidence, but accrual of patients in clinical trials is also key, according to Petros Grivas, M.D., Ph.D.

New Chemotherapy Combination Offers Improved Outcomes in Bladder Cancer

November 27th 2018

Patients with muscle-invasive bladder cancer who were treated with a dose-dense regimen of neoadjuvant chemotherapy followed by radical cystectomy (surgery to remove the urinary bladder) experienced more complete responses to treatment compared with the current standard of neoadjuvant chemotherapy.

Treatment Options for Bladder Cancer: What's New and What's Next

November 26th 2018

The treatment paradigm for bladder cancer has been quite exciting in the last few years, and even more is yet to come, according to Petros Grivas, M.D., Ph.D.

Managing Bladder Cancer in the Era of Cancer Immunotherapy

November 26th 2018

Although immunotherapies show promise for patients, there are still challenges ahead.

Combination with Higher Dose of Yervoy Shows Promise in Bladder Cancer

November 6th 2018

Patients with platinum-pretreated metastatic urothelial carcinoma who were treated with a higher dosage of Yervoy (ipilimumab) in combination with Opdivo (nivolumab) experienced improved survival and tolerable side effects, according to findings from the phase 1/2 CheckMate-032 trial.

Patients With High-Risk Non-Muscle Invasive Bladder Cancer Show Response to Keytruda

October 25th 2018

The immunotherapy agent Keytruda is showing promise for treating non-muscle invasive bladder cancer, according to a recent study.

Those in Remission from Bladder Cancer Report More Positive Experiences

October 23rd 2018

In a recent survey, individuals in remission reported a more positive experience with bladder cancer compared with their counterparts who currently have active disease.

New Research Says Universal Lynch Syndrome Testing Should Be Expanded

October 22nd 2018

While universal screening for Lynch syndrome is currently only recommended for patients with colorectal and endometrial cancers, a new study recently published in The American Journal of Surgical Pathology suggests this for patients with upper tract urothelial carcinoma, too.

Decreasing Opioid Use After Urologic Cancer Surgery

October 8th 2018

Can providers decrease opioid prescriptions after surgery, while still managing care adequately?

Immunotherapy's Role in Advanced Bladder Cancer Continues to Evolve

October 5th 2018

Immunotherapy has been a buzzworthy topic in the field of bladder cancer over the last couple of years. However, according to a Food and Drug Administration (FDA) safety warning, patients with metastatic disease may need to have their treatment altered.

Cancer Researchers Win Nobel Prize

October 2nd 2018

Immunotherapy pioneers James P. Allison and Dr. Tasuku Honjo have won the 2018 Nobel Prize in Physiology or Medicine for their research that eventually led to the use of immune checkpoint inhibitors to treat cancer.

Chemotherapy Before Surgery: Which Regimen is Best for Invasive Bladder Cancer?

September 27th 2018

Researchers determined that the use of methotrexate, vinblastine, doxorubicin and cisplatin before cystectomy may induce better outcomes for patients with advanced bladder cancer.

Genetic Test Aims to Prevent Over-Treatment, Lower Care Costs in Bladder Cancer

September 26th 2018

A new test that identifies which bladder cancer tumors will become invasive could help reduce health care costs and over-treatment in patients.

Subset of Cells in Bladder Cancer May Hinder Immunotherapy Outcomes

September 3rd 2018

Stromal cells – known to provide structure to one’s organs – found in bladder cancer may explain why some patients do not respond to Opdivo (nivolumab) treatment.

When Less Is More in Bladder Cancer Treatment

September 1st 2018

Some patients eligible for bladder surgery due to cancer may safely opt to preserve the organ.

A Double Whammy to Treat Bladder Cancer

August 31st 2018

After chemotherapy, immunotherapy has become the standard treatment for bladder cancer. Will it ever play a bigger role?